+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating new combination treatments for people with locally advanced or metastatic non-small cell lung cancer NSCLC in this Phase II, multi-center, open-label study. The study includes several sub-studies focused on different groups based on tumor genetics and PD-L1 levels, aiming to assess the safety, tolerability, and early anti-tumor effects of these novel regimens. This global study is conducted at approximately 80 centers across 10 countries. Participants receive different combinations of investigational drugs given by intravenous infusion, including rilvegostomig, ramucirumab, and Dato-DXd, depending on their assigned sub-study. Treatments continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. Each sub-study may have a safety run-in phase followed by a dose expansion phase to further evaluate the treatments. Throughout the study, participants undergo regular assessments to monitor tumor response, side effects, and drug levels in the blood. Researchers will track adverse events and measure outcomes like objective response rate, progression-free survival, and overall survival over an average of three years. The study also evaluates pharmacokinetics and immune response to the treatments to better understand how they work and their safety profile.

Age: 18Years +All GendersPhase 2
83 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Enzeavour Pancreatic Cancer assay as a screening tool for pancreatic cancer in asymptomatic adults in Japan. This nationwide, multicenter, prospective, single-arm feasibility study aims to assess the detection rate and positive predictive value of this blood-based test in routine health checkups and cancer screening programs. Pancreatic cancer is often diagnosed late, and this study seeks to develop an effective population-based screening strategy. Participants will have blood samples collected during routine health checkups or organized cancer screenings. The Enzeavour assay measures the activity of three specific enzymes at a single-molecule level and combines four biomarkers into a composite score. Those with an Enzeavour Score above 0.369 will be referred for further diagnostic imaging such as MRCP, EUS, or contrast-enhanced CT as needed. This diagnostic work-up follows the initial screening result. Throughout the study, which follows participants for 12 months after the blood draw, researchers will monitor pancreatic cancer detection rates and the assays positive predictive value. Participants will be evaluated through blood tests and any indicated diagnostic imaging. The study will include approximately 10,000 adults and aims to provide real-world data for planning future trials. The total duration of participation varies based on follow-up needs.

Age: 20Years +All GendersPhase Not Applicable
69 locations